Oregon Public Employees Retirement Fund Buys 117 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Oregon Public Employees Retirement Fund lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,633 shares of the company’s stock after buying an additional 117 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Neurocrine Biosciences were worth $2,816,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Caprock Group LLC bought a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $236,000. Plato Investment Management Ltd lifted its stake in Neurocrine Biosciences by 2,481.9% during the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after purchasing an additional 10,548 shares during the last quarter. Swiss National Bank lifted its stake in Neurocrine Biosciences by 1.4% during the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock worth $34,416,000 after purchasing an additional 4,100 shares during the last quarter. Tri Ri Asset Management Corp bought a new stake in Neurocrine Biosciences during the third quarter worth $3,236,000. Finally, KBC Group NV lifted its stake in Neurocrine Biosciences by 78.3% during the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after purchasing an additional 8,332 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on NBIX. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. UBS Group upped their target price on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research note on Thursday, January 30th. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 18th. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $166.90.

Neurocrine Biosciences Trading Down 0.1 %

Shares of Neurocrine Biosciences stock opened at $117.51 on Friday. The business has a 50-day moving average price of $135.23 and a two-hundred day moving average price of $128.73. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The company has a market cap of $11.72 billion, a P/E ratio of 35.72, a PEG ratio of 0.77 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Equities research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences declared that its board has initiated a share buyback program on Friday, February 21st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 4.2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 272 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the sale, the insider now directly owns 2,507 shares in the company, valued at approximately $346,216.70. This trade represents a 9.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Julie Cooke sold 1,740 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $152.89, for a total transaction of $266,028.60. Following the transaction, the insider now directly owns 18,202 shares in the company, valued at $2,782,903.78. This trade represents a 8.73 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 234,269 shares of company stock worth $34,053,879. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.